Sermorelin is delivered the same way in every published trial: as a subcutaneous injection, not an intramuscular one. What that generally involves — needle choice, injection sites, and how used supplies get disposed of — is well studied for self-administered subcutaneous therapy broadly, even where sermorelin-specific data does not exist. This page describes what a prescriber or pharmacy typically covers with a patient, in general terms. It is not a set of steps to follow, and it does not replace your own pharmacy’s instructions for its specific product.
Subcutaneous, not intramuscular
Every published sermorelin trial used subcutaneous delivery. The adult trial injected 10 micrograms per kilogram subcutaneously, nightly [3] — the regimen covered in the dosage breakdown. A pediatric trial delivered GHRH(1-29) by continuous subcutaneous infusion for up to a year [4], and a comparative pediatric trial used continuous subcutaneous infusion as well [5]. None of the outcome data behind sermorelin comes from an intramuscular injection.
That distinction is not cosmetic. A wider body of literature covers self-administered subcutaneous hormone therapy, built mostly around insulin, the most heavily studied injectable in this category. It treats an accidental intramuscular injection as a real technique issue, not a trivial one — it can change how a drug is absorbed, and it has been flagged as a safety concern for certain compounds [1]. None of that research involves sermorelin specifically. It describes subcutaneous injection technique broadly, in a different drug class entirely. A compounding pharmacy’s own instructions for its specific product are the source that should govern over any general description here.
Needle length and gauge
The most detailed modern consensus on subcutaneous self-injection technique comes from the Forum for Injection Technique and Therapy — a 2015 workshop of 183 clinicians, with recommendations published the following year. Their central finding: the shortest needles (currently the 4-mm pen and 6-mm syringe needles) are described as safe, effective, and less painful, and recommended as the first-line choice across patient categories [1]. That recommendation was built on insulin injection data, not on any sermorelin-specific study. No trial has tested needle length as a variable in sermorelin delivery. It is included here because it is the best-studied general answer to a question sermorelin research itself has never asked.
Compounded peptide vials also vary in how they are reconstituted and drawn up, which affects the syringe and needle a pharmacy will actually dispense — a detail covered separately in how sermorelin vials are reconstituted. That detail sits with the specific vial and pharmacy, not with any published trial.
Site rotation
The same consensus group flagged a specific, well-documented complication of repeated injections into the same small area: lipohypertrophy, a frequent complication of insulin therapy that distorts drug absorption, which the group says injections and infusions should avoid by rotating sites correctly [1]. That finding is specific to insulin therapy. But the underlying mechanism — repeated trauma to the same patch of tissue changing how it absorbs a drug — is not unique to insulin. It is a reasonable, general argument for rotating injection sites with any subcutaneous therapy delivered nightly over weeks or months, sermorelin included. No sermorelin trial measured absorption at a rotated site against a fixed one.
The supplies that typically come with a compounded kit
A compounding pharmacy dispensing an injectable peptide typically ships more than the vial itself — usually alcohol swabs, a supply of syringes and needles sized to the product, and often a small sharps container. Vials are generally reconstituted with bacteriostatic water and then kept refrigerated, a storage detail specific to each pharmacy’s own formulation and covered in how to store sermorelin. None of that is standardized across sellers. A kit’s exact contents and storage instructions come from the dispensing pharmacy, not from any published trial.
Sharps disposal
This is the part of the routine with the clearest general safety literature behind it, and the least sermorelin-specific data. A review of home self-injection practice found that between 8 and 9 million Americans are self-injecting medication at home, and that most of the used needles are thrown directly into the household trash [2]. The same 2016 injection-technique consensus states plainly that inappropriate sharps disposal poses a real infection risk from blood-borne pathogens, a risk it describes as manageable with proper training, effective disposal strategies, and safety devices [1]. Community guidance for safe disposal generally points toward FDA-cleared sharps containers, pharmacy take-back programs, or mail-back services. Loose disposal in household trash is exactly what that guidance is written to discourage. This is standard public-health practice for any at-home injection therapy, sermorelin included.
What the sermorelin literature itself says about injection sites
Almost nothing. The only injection-site safety data inside a sermorelin trial comes from a pediatric comparative study: of 60 children receiving daily GHRH(1-29) dosing over six months, three reported mild irritation at the injection site, and no serious side effects were recorded [5]. That is a single, small, pediatric data point. It is not a study of technique, site rotation, or needle gauge, and it is not drawn from the adult dosing regimen sold today — it also predates the compounded, self-injected products marketed under this name now. Everything above about needle length, rotation, and disposal is general subcutaneous-injection science, applied by extension. None of it is sermorelin-specific research. For what the same literature says about a missed dose rather than a technique question, see missing a sermorelin dose.
The bottom line
Sermorelin is injected the way every trial injected it: subcutaneously. Beyond that single fact, the specific technique guidance that exists — needle length, site rotation, safe disposal — comes from the much larger literature on subcutaneous self-injection generally. None of it comes from a sermorelin trial. A pharmacy’s own instructions for its specific formulation and delivery device are the source that should govern in practice. Sellers that publish their own kit contents and disposal instructions rather than leaving a buyer to guess are listed on the injections board.